MET/HGF Signaling Pathway in Ovarian Carcinoma: Clinical Implications and Future Direction (Q36520263)

14 August 2017

MET/HGF Signaling Pathway in Ovarian Carcinoma: Clinical Implications and Future Direction (English)

1 reference

14 August 2017

1 reference

3

Tanja Pejovic

1 reference

14 August 2017

Paulette Mhawech-Fauceglia

series ordinal

1

1 reference

PMCID

3540829

14 August 2017

Michelle Afkhami

series ordinal

2

1 reference

14 August 2017

25 December 2012

1 reference

Pathology Research International

14 August 2017

1 reference

14 August 2017

2012

1 reference

14 August 2017

960327

1 reference

Creative Commons Attribution 3.0 Unported

14 August 2017

start time

25 December 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Targeting the HGF/Met signaling pathway in cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

HGF/c-MET targeted therapeutics: novel strategies for cancer medicine.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

Assessment of hepatocyte growth factor in ovarian cancer mortality

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

Ovarian cancer development and metastasis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

c-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

Small molecule c-Met kinase inhibitors: a review of recent patents

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

Novel therapeutic inhibitors of the c-Met signaling pathway in cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

HGF/MET signaling in ovarian cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

The Met tyrosine kinase receptor in development and cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

Targeting the c-Met signaling pathway in cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

Activation of p70S6K induces expression of matrix metalloproteinase 9 associated with hepatocyte growth factor-mediated invasion in human ovarian cancer cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

Somatic mutations lead to an oncogenic deletion of met in lung cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

p38 MAPK turns hepatocyte growth factor to a death signal that commits ovarian cancer cells to chemotherapy-induced apoptosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

Progressive changes in Met-dependent signaling in a human ovarian surface epithelial model of malignant transformation.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

Hepatocyte growth factor sensitizes human ovarian carcinoma cell lines to paclitaxel and cisplatin

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

Met, metastasis, motility and more

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

Ovarian cancer: strategies for overcoming resistance to chemotherapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

Scatter-factor and semaphorin receptors: cell signalling for invasive growth

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

Expression of HGF/NK4 in ovarian cancer cells suppresses intraperitoneal dissemination and extends host survival

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

Histopathologic grading of ovarian carcinoma: a review and proposal

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

Tumor invasion: role of growth factor-induced cell motility

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

Hepatocyte growth factor (HGF) in ovarian epithelial tumour fluids stimulates the migration of ovarian carcinoma cells.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

Comparison of c-met expression in ovarian epithelial tumors and normal epithelia of the female reproductive tract by quantitative laser scan microscopy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

Hepatocyte growth factor stimulates motility, chemotaxis and mitogenesis in ovarian carcinoma cells expressing high levels of c-met

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

Emerging multipotent aspects of hepatocyte growth factor

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

Molecular characteristics of HGF-SF and its role in cell motility and invasion

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

Hepatocyte growth factor: Molecular structure and implications for a central role in liver regeneration

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

Hepatocyte growth factor: molecular structure, roles in liver regeneration, and other biological functions

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

Expression and action of hepatocyte growth factor in human and bovine normal ovarian surface epithelium and ovarian cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

Comparison of the usefulness between a new universal grading system for epithelial ovarian cancer and the FIGO grading system.

28 June 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F960327

MET receptor tyrosine kinase sequence alterations in differentiated thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F960327

Overexpression of the Met/HGF receptor in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F960327

Comparison of HGF (hepatocyte growth factor) levels of epithelial ovarian cancer cyst fluids with benign ovarian cysts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F960327

Profiling of protein kinases in the neoplastic transformation of human ovarian surface epithelium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F960327

Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F960327

Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3540829

Genes regulated by hepatocyte growth factor as targets to sensitize ovarian cancer cells to cisplatin

21 September 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F960327

Pathway specificity for Met signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F960327

Grading ovarian serous carcinoma using a two-tier system

21 January 2018

1 reference

12 December 2020

Classification and Staging of Malignant Tumours in the Female Pelvis

1 reference

12 December 2020

Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas

1 reference

12 December 2020

1 reference

12 December 2020

Prognostic factors for surgical outcome and survival in 447 women treated for advanced (FIGO-stages III-IV) epithelial ovarian carcinoma

1 reference

12 December 2020

c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion

1 reference

12 December 2020

Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (A

1 reference

12 December 2020

Synergistic effects of epidermal growth factor and hepatocyte growth factor on human ovarian cancer cell invasion and migration: role of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase

1 reference

12 December 2020

Tubal origin of 'ovarian' low-grade serous carcinoma

1 reference

12 December 2020

Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas

1 reference

12 December 2020

Coexpression of hepatocyte growth factor-Met: an early step in ovarian carcinogenesis?

1 reference

12 December 2020

The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma

1 reference

12 December 2020

Identifiers

DOI

10.1155/2012/960327

1 reference

14 August 2017

1 reference

14 August 2017

1 reference

PMCID

3540829